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We report the results of a consensus conference on the diagnosis 
of multiple system atrophy (MSA). We describe the clinical 
features of the disease, which indude four domains: autonomic 
failure/urinary dysfunction, parkiusonism and cerebellar 
ataxia, and corticospinal dysfunction. We set criteria to define 
the relative importance of these features. The diagnosis of possi- 
ble MSA requires one criterion plus two features from separate 
domains. The diagnosis of probable MSA requires the criterion 
for autonomic failure/urinary dysfimction plus poor levodopa 
responsive parkiusonism or cerebella* ataxia. The diagnosis of 
definite MSA requires pathological confirmation. 
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Multiple system atrophy (MSA), a progressive neurodegen- 
erative disease of undetermined etiology, occurs sporadically 
and causes parkinsonism and cerebellar, autonomic, urinary, 
and pyramidal dysfunction in many combinations [1-4]. 
The disease affects both sexes, usually beginning in middle 
age and progressing over intervals of 1 to 18 years, with a 
median survival of 9.3 years from the first symptom [5,6]. 
The parkinsonian features include bradykinesia with rigidity, 
postural instability, hypokinetic speech, and often tremor, 
usually with a poor or unsustained response to chronic levo- 
dopa therapy. The cerebellar dysfunction consists of ataxia 
of gait, limb movements and speech, and disorders of extra- 
ocular movements [7]. Autonomic insufficiency results in 
orthostatic hypotension, often with an inadequate heart rate 
response to standing, male erectile dysfunction (MED), con- 
stipation, and decreased sweating [8,9]. Urinary symptoms 
include urgency, frequency, nocturia, incomplete bladder 
emptying, and incontinence [10]. The diagnosis of MSA 
requires primarily clinical assessment; however, a number 
of laboratory tests may help to support the diagnosis. 
The neuropathological changes consist of a high density 
of glial cytoplasmic inclusions (GCIs) in association with 
degenerative changes in some or all of the following struc- 
tures: putamen, caudate nucleus, globus pallidus, substantia 
nigra, locus ceruleus, inferior olives, pontine nuclei, cerebel- 
lar Purkinje cells, autonomic nuclei of the brainstem, and 
the intermediolateral cell columns and Onus nucleus in 
the spinal cord [11,12]. GCIs are ubiquitin-, tan- and 
a-synuclein-positive oligodendroglial inclusions [12]. 
Some efforts have been made to establish diagnostic crite- 
ria [4], but no consistent detailed guidelines have been devel- 
oped. Accordingly, a consensus conference was convened on 
April 23 and 24, 1998 in Minneapolis, Minnesota, cospon- 
sored by the American Autonomic Society and the American 
Academy of Neurology. The goal of the conference was to 
develop guidelines for the diagnosis of MSA. We achieved 
consensus on the items listed below and shown in Tables 
1, 2, and 3. These guidelines have not yet been validated, 
and will almost certainly require further modification in the 
light of future experience. 
Clinical domains 
Autonomic and urinary dysfunction 
Orthostatic hypotension (OH) may indicate autonomic fail- 
ure and can be asymptomatic or symptomatic. When symp- 
tomatic, it typically occurs after the onset of MED and 
urinary symptoms. Symptoms of OH result from cerebral 
hypoperfusion, and syncope may occur. The consensus con- 
ference determined that the clinical diagnosis of probable 
MSA requires a reduction of systolic blood pressure by at 
least 30 mm Hg or of diastolic blood pressure by at least 15 
mm Hg within 3 minutes of standing from the recumbent 
* Please see "Conference Participants" section at the end of this article for 
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Table 1. Clinical domains, features, and criteria used in the 
diagnosis of MSA* 
I. Autonomatic and urinary dysfunction 
A) Autonomic and urinary features 
1. Orthostatic hypotension (by 20 mm Hg systolic or 10 
mm Hg diastolic) 
2. Urinary incontinence or incomplete bladder emptying 
B) Criterion for autonomic failure or urinary dysfunction in 
MSA 
Orthostatic fall in blood pressure (by 30 mm Hg systolic or 15 
mm Hg diastolic) or urinary incontinence (persistent, involuntary 
partial or total bladder emptying, accompanied by erectile dysfunc- 
tion in men) or both 
II. Parkinsonism 
A) Parkinsonian features 
1. Bradykinesia (slowness of voluntary movement with 
progressive reduction in speed and am 31itude dur- 
ing repetitive actions) 
2. Rigidity 
3. Postural instability (not caused by primary visual, ves- 
tibular, cerebellar, or proprioceptive dysfunction) 
4. Tremor (postural, resting, or both) 
B) Criterion for parkinsonism in MSA 
Bradykinesia plus at least one of items 2 to 4 
II1. Cerebellar dysfunction 
A) Cerebellar features 
1. Gait ataxia (wide based stance with steps of irregular 
length and direction) 
2. Ataxic dysarthria 
3. Limb ataxia 
4. Sustained gaze-evoked nystagmus 
B) Criterion for cerebellar dysfunction in MSA 
Gait ataxia plus at least one of items 2 to 4 
IV. Corticospinal tract dysfunction 
A) Corticospinal tract features 
1. Extensor plantar responses with hyperreflexia 
B) Corticospinal tract dysfunction in MSA: no corticospinal 
tract features are used in defining the diagnosis of 
MSA 
*A feature (A) is a characteristic of the disease and a criterion 
(B) is a defining feature or composite of features required for diag- 
nosis. 
position. Frequently this is accompanied by an inadequate 
increase in heart rate (less than 10 beats per minute). We 
note that this is a more pronounced degree of OH than 
established previously [4]. MED appears early and affects 
virtually all male patients with MSA, but the symptom has 
Table 2. Diagnostic categories of MSA* 
I. Possible MSA: One criterion plus two features from separate 
domains. When the criterion is parkinsonism, a poor levo- 
dopa response qualifies as one feature (hence only one 
additional feature is required). 
II. Probable MSA: Criterion for: autonomic failure/urinary dysfunc- 
tion plus poor levodopa-responsive parkinsonism or cerebel- 
lar dysfunction. 
Ill. Definite MSA: Pathologically confirmed by the presence of a 
high density of glial cytoplasmic inclusions in association 
with a combination of degenerative changes in the nigrostria- 
tal and olivopontocerebellar pathways. 
*The features and criteria for each clinical domain are shown in 
Table 1. 
Table 3. Exclusion criteria for the diagnosis of MSA 
I. History 
Symptomatic onset under 30 years of age 
Family history of a similar disorder 
Systemic diseases or other identifiable causes for features 
listed in Table 1 
Hallucinations unrelated to medication 
I1. Physical examination 
DSM criteria for dementia 
Prominent slowing of vertical saccades or vertical supranu- 
clear gaze palsy* 
Evidence of focal cortical dysfunction such as aphasia, alien 
limb syndrome, and parietal dysfunction 
III. Laboratory Investigation 
Metabolic, molecular genetic, and imaging evidence of an 
alternative cause of features listed in Table 1 
*In practice, MSA is most frequently confused with Parkinson's 
disease or progressive supranuclear palsy (PSP) [25]. Mild limita- 
tion of upward gaze alone is nonspecific, whereas a prominent 
(>50%) limitation of upward gaze or any limitation of downward 
gaze suggests PSP, Before the onset of vertical gaze limitation, 
a clinically obvious slowing of voluntary vertical saccades is usually 
easily detectable in PSP and assists in the early differentiation of 
these two disorders [26]. 
low specificity. Urinary frequency, urgency, incontinence, or 
incomplete bladder emptying also occur early and commonly. 
Parkinsonism 
The majority of MSA patients develop parkinsonian features 
at some stage of the disorder. All these patients have bradyki- 
nesia; rigidity, postural instability, and tremor also often 
occur. The tremor is usually irregular and postural, often 
incorporating myoclonus. A classical pill-rolling parkinso- 
nian rest tremor is uncommon. The parkinsonism in MSA 
can be asymmetric. The dysarthria is mainly hypokinetic, 
often mixed with other components [ 13]. The parkinsonian 
features usually respond poorly to chronic levodopa therapy; 
however, up to 30% of patients show a clinically significant 
response to levodopa therapy at some time in the course, 
but the response is usually sustained for less than five years 
[5,14,15]. These are the most challenging patients for accu- 
rate diagnosis. 
Cerebellar dysfunction 
Ataxia of gait, the most common cerebellar feature of MSA, 
often occurs accompanied by dysarthria, limb ataxia, and 
sometimes gaze-evoked nystagmus and ocular dysmetria. A 
common finding is saccadic pursuit movements. The dysar- 
thria in patients with predominantly cerebellar dysfunction 
is mainly ataxic, often mixed with other components [13]. 
Corticospinal dysfunction 
Extensor plantar responses with hyperreflexia occur in about 
50% of MSA patients. Corticospinal signs can contribute 
to the diagnosis, but are less important than abnormalities 
in the other domains. 
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Response to levodopa 
Levodopa responsiveness should be tested by administering 
escalating doses (with a peripheral decarboxylase inhibitor) 
over a 3-month period up to at least I g per day (if necessary 
and if tolerated). A positive response is defined as clinically 
significant improvement. This should be demonstrated by 
objective evidence such as an improvement of 30% or more 
on part III (motor examination) of the Unified Parkinson's 
Disease Rating Scale [16]. 
Laboratory investigations 
Autonomic function tests, sphincter electromyography 
(EMG), and neuroimaging may be used to support the 
diagnosis, and neuroimaging is helpful in excluding other 
conditions. The abnormalities described below have been 
defined principally in clinically well-established cases rather 
than in the early stages of the disease. In the early stages, 
the tests may give equivocal results. We consider it premature 
to incorporate laboratory results into the entirely clinical 
guidelines that we established, but envision the future devel- 
opment of "Laboratory Supported" diagnostic categories. 
Assessment of autonomic function can be assisted by a 
comprehensive battery that evaluates the distribution and 
severity of sudomotor, cardiovagal, and sympathetic adrener- 
gic deficits [17,18]. Autonomic function tests may help sepa- 
rate MSA from Parkinson's disease and from idiopathic 
cerebellar degenerations [8]. 
Sphincter EMG can be useful in the diagnosis of MSA. 
Analysis of individual motor unit potentials recorded from 
the external anal sphincter usually shows changes indicating 
chronic reinnervation, with markedly prolonged motor 
units [10,19]. 
Magnetic resonance imaging (MRI) can assist the evalua- 
tion by detecting abnormalities ofstriatum, cerebellum, and 
brainstem, but can be normal in up to 20% of cases [20]. 
Striatal abnormalities may include putaminal atrophy, slit- 
like signal change at the posterolateral putaminal margin, 
and hypointensity of the putamen relative to the globus 
pallidus [21]. Infratentorial abnormalities include cerebellar 
and pontine atrophy, and signal change in the pons and 
middle cerebellar peduncles [22]. Studies are in progress 
to evaluate the utility of magnetic resonance spectroscopy, 
positron emission tomography, and single photon emis- 
sion tomography. 
Diagnostic categories 
We established three diagnostic categories reflecting differing 
levels of certainty: definite, probable, and possible. The diag- 
nosis of definite MSA can only be made after neuropatholog- 
ical examination of the central nervous system revealing the 
characteristic density and distribution of GCIs and degenera- 
tive changes outlined above. The diagnosis of probable or 
possible MSA can be made using different combinations of 
clinical domains, criteria, and features, as indicated in Tables 
1 and 2. Exclusion criteria are shown in Table 3. 
Terminology 
MSA is a distinct clinicopathological entity. The term should 
not be used to describe other neurodegenerative diseases 
affecting multiple systems. The use of confusing terms such 
as "multisystem degeneration" for MSA is inappropriate and 
now should be discouraged. We recommend designating 
patients as having MSA-P if parkinsonian features predomi- 
nate or MSA-C if cerebellar features predominate [23,24]. 
These terms are intended to replace the striatonigral degener- 
ation (SND) and sporadic olivopontocerebellar atrophy 
(sOPCA) types of MSA, respectively. The term Shy Drager 
syndrome has been widely misused, and is no longer useful. 
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